Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05680792
Other study ID # IPH/OAU/12/1574
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 10, 2020
Est. completion date January 31, 2023

Study information

Verified date September 2023
Source Obafemi Awolowo University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to 1. determine the most effective biological sampling method that best describe the pharmacokinetics nitazoxanide/tizoxanide and to; 2. evaluate the clinical significance of the pharmacokinetics interaction between nitazoxanide (1000mg twice daily) and atazanavir/ritonavir (300mg/100mg). Participants will be given 1000mg oral nitazoxanide taken twice daily for seven days. After a washout period of three weeks, they will receive 1000mg oral nitazoxanide with atazanavir/ritonavir (taken orally at 300/100 mg). Five millimetres of whole blood or swab or saliva samples will be collected from them at 0.5, 1, 2, 4, 6, 8 and 12 hours after dose on day 1, 5 and 7. The pharmacokinetic of nitazoxanide when administered alone and alongside atazanavir/ritonavir will be compared to see if concomitant administration of nitazoxanide and atazanavir/ritonavir affect nitazoxanide pharmacokinetics


Description:

Nitazoxanide is an antiprotozoal drug with a well-understood and documented safety profile. It was first approved by the US Food and Drug Administration (FDA) in July 2004 for the treatment of diarrhoea caused by Giardia lamblia or Cryptosporidium parvum in adults (≥ 18 years) and paediatrics (1-17 years). Nitazoxanide has also demonstrated in-vitro anti-SARS-CoV-2 activity. A review of in vitro studies reporting the anti-coronavirus activity of nitazoxanide and its active metabolite, tizoxanide, is available. Nitazoxanide was among the three top inhibitors of coronavirus replication, resulting in a reduction of 6 log10 in virus titer with an IC50 of 1.0 µM. The major circulating metabolite of nitazoxanide is tizoxanide, and it has also been confirmed to have activity against SARS-CoV-216. Both suppress the cytopathic effect of SARS-CoV-2. Nitazoxanide is also active against the influenza A virus and was shown to reduce symptom duration in uncomplicated acute influenza. Since SARS-CoV-2 shares almost 80% of the genome with SARSCoV19 and almost all encoded proteins of SARS-CoV-2 are homologous to SARS-CoV proteins, nitazoxanide and its metabolite tizoxanide with demonstrated activity against SARS-CoV are likely to be effective against SARS-CoV-2. Since the virus replicates quickly, antivirals must remain active across their dosing interval. Therefore, enhanced drug concentration will be needed in the lung throughout the dosing interval. The HIV protease inhibitor, atazanavir (boosted with ritonavir), has been shown to inhibit the major protease enzyme required for viral polyprotein processing during coronavirus replication. It also blocks pro-inflammatory cytokine production. Similar to nitazoxanide, atazanavir has been shown to achieve effective concentration in the pulmonary tissues at the approved dose of 300 mg in combination with 100 mg of ritonavir, with even more favourable ratios when compared to in vitro activities generated in human cell models. Therefore, based on these considerations, the combination of nitazoxanide (taken orally at 1000 mg twice daily) and atazanavir/ritonavir (taken orally at 300/100 mg once daily) is being considered for selection for intervention for the treatment of COVID-19. Hence, this study wants to evaluate the clinical usefulness of the combination of these drugs. The approach is to characterise the extent of drug-drug interaction of nitazoxanide and atazanavir/ritonavir when 1000 mg nitazoxanide is taken two times daily in combination with 300/100 mg atazanavir/ritonavir before deploying the combination for the intervention.


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date January 31, 2023
Est. primary completion date January 10, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 41 Years
Eligibility Inclusion Criteria: - The study population will include both male and female healthy volunteers that are eighteen years or above - non-smokers, non-alcoholics, had not taken any medication or coffee 2 weeks before participating, were non-pregnant and non-breastfeeding Exclusion Criteria: - Pregnant women will be excluded from the study. Moreover, volunteers who have been on any other drugs in the last two weeks will also be excluded from the study. - Exclusion criteria included any sickness or reaction to the study drugs.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nitazoxanide
1000 mg nitazoxanide tablets twice daily. The drug will be administered after meal for 5 days
Atazanavir/ritonavir
300/100 mg atazanavir/ritonavir tablets in the evening once daily, to be administered after meal for 5 days.

Locations

Country Name City State
Nigeria Obafemi Awolowo University Ile-Ife Osun

Sponsors (2)

Lead Sponsor Collaborator
Obafemi Awolowo University University of Liverpool

Country where clinical trial is conducted

Nigeria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Minimum plasma concentration (Cmin) Tizoxanide minimum plasma concentration with or without atazanavir/ritonavir After the first dose (Day 1)
Primary Minimum plasma concentration (Cmin) Tizoxanide minimum plasma concentration with or without atazanavir/ritonavir At Day 5
Primary Maximum plasma concentration (Cmax) Tizoxanide maximum plasma concentration with or without atazanavir/ritonavir After the first dose (Day 1)
Primary Maximum plasma concentration (Cmax) Tizoxanide maximum plasma concentration with or without atazanavir/ritonavir At Day 5
Primary Area under the concentration-time curve (AUC) Tizoxanide Area under the concentration-time curve with or without atazanavir/ritonavir After the first dose (Day 1)
Primary Area under the concentration-time curve (AUC) Tizoxanide Area under the concentration-time curve with or without atazanavir/ritonavir At Day 5
See also
  Status Clinical Trial Phase
Completed NCT04645940 - Fruquintinib Food Effect and Proton Pump Inhibitor Study Phase 1
Completed NCT04540965 - Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects Phase 1
Completed NCT04531072 - Effect of Atazanavir-ritonavir on the Pharmacokinetics and Toxicity of Lumefantrine Phase 4
Completed NCT03385525 - Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074 Phase 1
Completed NCT05137548 - A Drug-Drug Interaction Study Between ATI-2173 and Tenofovir Disoproxil Fumarate in Healthy Subjects Phase 1
Not yet recruiting NCT05525351 - The Application and Validation of Triple Drug Response Surface Models on Density Spectral Array in Clinical Anesthesia
Terminated NCT01980342 - Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz Phase 4
Completed NCT04080596 - DDI Study to Investigate the Impact of Itraconazole on the Pharmacokinetics of Dorzagliatin Phase 1
Recruiting NCT04593680 - Assessment of Drug-drug Interactions Between Masculinizing Hormone Therapy and Antiretroviral Agents Concomitantly for Pre-exposure Prophylaxis Among Transgender Men N/A
Active, not recruiting NCT04590417 - Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomitantly for Pre-exposure Prophylaxis Among Transgender Women N/A
Completed NCT05633147 - Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam Phase 1
Completed NCT02391688 - Evaluation of the Potential Pharmacokinetic Interactions Between Probe Drugs in the Geneva Phenotyping Cocktail Phase 1
Completed NCT00806299 - Loperamide Grapefruit Juice Interaction PK Trial Phase 1
Completed NCT03336346 - Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana
Completed NCT04818086 - Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder Phase 1/Phase 2
Completed NCT03187015 - A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects Phase 1
Not yet recruiting NCT04463576 - Drug Interactions in Hospital Information System. The PRoSIT System..
Not yet recruiting NCT03920566 - The Effect of ENZAlutamide on the Anti-Xa Levels of Patients Receiving DOACs
Completed NCT03011996 - To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration Phase 1
Completed NCT04902105 - Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite Phase 1